Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 8/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | EDNRA | P25101 | 1/20 | 0.38 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2095977 | 0.92 | DPP4 (0.43) | MAPTLMNACYP2C9ATP6V1B2TBXA2R | |
| SCHEMBL2094103 | 0.84 | DPP4 (0.48) | MAPTLMNACYP2C9ATP6V1B2TBXA2R | |
| SCHEMBL2092595 | 0.83 | GNRHR (0.38) | GNRHRMAPTP2RX7TP53POLB | |
| SCHEMBL2093477 | 0.83 | LMNA (0.46) | GNRHRMAPTP2RX7LMNACYP2C9 | |
| SCHEMBL2095363 | 0.83 | LMNA (0.46) | GNRHRMAPTP2RX7LMNACYP2C9 | |
| SCHEMBL2092621 | 0.82 | CHRM1 (0.48) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL2095372 | 0.81 | DPP4 (0.46) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL2092590 | 0.81 | GNRHR (0.50) | GNRHRMAPTP2RX7TP53POLB | |
| SCHEMBL2092907 | 0.81 | CHRM1 (0.37) | MAPTLMNAEDNRATP53DPP4 | |
| SCHEMBL2095535 | 0.81 | HRH4 (0.38) | GNRHRTP53POLBNTRK1MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | claimed |
| US-8163769-B2 | 1,8-naphthyridine derivatives | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | GNRHR 4352/4885MAPT 4388/4885P2RX7 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.